Clinical trials: Acne
Acne Vulgaris
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or…
- Trial name
- NCT01706250
- Testing
- MAXCLARITY II (2.5% BPO) Foam Cleanser, MAXCLARITY II (2.5% BPO) Foam Treatment, MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
- Volunteers
- 20 people
- Sponsor
- Stiefel, a GSK Company
Acne Scars
Clinical Evaluation of Fractional Radiofrequency for the Treatment of Acne Scarring
Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring.
- Trial name
- NCT03767153
- Testing
- Venus Viva
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Venus Concept
Acne
The Use of Oracea and Epiduo Forte in Severe Acne Patients
This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4, 8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline.
- Trial name
- NCT03457636
- Testing
- Doxycycline Anhydrous 40 MG, Adapalene/Benzoyl Peroxide Gel 0.3-2.5%
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Acne Vulgaris
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
This study will evaluate the effect of dapsone gel in female subjects with skin of color (Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.
- Trial name
- NCT02032407
- Testing
- Dapsone Gel
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Allergan
Acne Inversa
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks.
- Trial name
- NCT04092452
- Testing
- PF-06650833, PF-06700841, PF-06826647
- Where
- 77 sites in United States, Australia and 1 more
- Volunteers
- 194 people
- Sponsor
- Pfizer
Acne Vulgaris
Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel
To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters…
- Trial name
- NCT01522456
- Testing
- Epiduo Gel, Retin-A Micro Microsphere 0.1%
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
- Trial name
- NCT05550337
- Testing
- Trifarotene 0.005 % Topical Cream, AKLIEF®
- Where
- 14 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Acne Vulgaris
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
- Trial name
- NCT02189629
- Testing
- CD5789 (trifarotene)
- Where
- 32 sites in United States, Czechia and 2 more
- Volunteers
- 453 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
- Trial name
- NCT02566369
- Testing
- CD5789 (trifarotene) 50μg/g cream
- Where
- 124 sites in United States, Canada and 3 more
- Volunteers
- 1,208 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
- Trial name
- NCT02556788
- Testing
- CD5789 (trifarotene) 50µg/g Cream
- Where
- 81 sites in United States, Czechia and 6 more
- Volunteers
- 1,212 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and effective for treating acne on the trunk (the main part of the body that does not include the arms, legs, and head).
- Trial name
- NCT00722761
- Testing
- drospirenone and ethinyl estradiol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Acne Vulgaris, Acne
Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris
Acne vulgaris is a multifactorial, highly prevalent dermatologic condition that results in visible lesions that can be quite disfiguring.
- Trial name
- NCT02431494
- Testing
- Blue light phototherapy, Microcurrent therapy, Combination of BLP and Microcurrent
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Nova Southeastern University
Acne
Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo
The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
- Trial name
- NCT01135069
- Testing
- Tretinoin microsphere 0.1%, Brand Retin-A Micro tretinoin microsphere gel 0.1%
- Where
- United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Spear Pharmaceuticals
Scarring, Acne
Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment
The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece…
- Trial name
- NCT03430921
- Testing
- Enlighten™ Laser and a MLA Attachment
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Intracranial Pressure Increase
Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure
The purpose of this study is to evaluate the vision and posterior segment of eyes in children and young adults less than 22 years of age with risk, suspicion, or past medical history significant for elevated intracranial pressure…
- Trial name
- ICP (NCT03286426)
- Testing
- Pictor
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Duke University
Acne Vulgaris
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe…
- Trial name
- NCT05080764
- Testing
- 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biofrontera Inc.
Acne Vulgaris
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
- Trial name
- NCT02815267
- Testing
- FMX-101, 4% minocycline foam, Vehicle Foam
- Where
- 31 sites in United States, Dominican Republic
- Volunteers
- 466 people
- Sponsor
- Vyne Therapeutics Inc.
Acne
Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne
Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group comparison study in subjects with severe acne vulgaris on the face.
- Trial name
- POWER (NCT01474590)
- Testing
- Epiduo/Tactuo, vehicle gel, doxycycline 200mg
- Where
- 25 sites in Canada
- Volunteers
- 266 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Study of a New Drug Treatment for Acne
A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.
- Trial name
- NCT01326780
- Testing
- 1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA
- Where
- 18 sites in United States
- Volunteers
- 431 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris, Pediatrics
Subantimicrobial Doxycycline in Acne
Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric…
- Trial name
- NCT05399290
- Testing
- Doxycycline Hyclate
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Michigan State University